Novartis

Who are the 10 Most Innovative Biopharma Companies?
Who are the 10 Most Innovative Biopharma Companies?
BioSpace
innovation
Regeneron
Verily
Illumina
Biogen
Bayer
Bluebird Bio
Novartis
GSK
Genentech
Amgen
Flag link:
Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public
Novartis' David Lennon on next steps for AveXis, selling Zolgensma's price to the public
BioPharma Dive
Novartis
SMA
AveXis
Zolgensma
drug pricing
Flag link:
Novartis Starts 2020 a Step Ahead of Other Big Pharmas with the Most Newly Approved Drugs
Novartis Starts 2020 a Step Ahead of Other Big Pharmas with the Most Newly Approved Drugs
Motley Fool
Novartis
FDA
drug approvals
Flag link:
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
Motley Fool
AbbVie
Boehringer Ingelheim
Skyrizi
Novartis
Cosentyx
psoriasis
Flag link:
JPM: New Novartis pharma chief rethinks its drug-launch formula
JPM: New Novartis pharma chief rethinks its drug-launch formula
Fierce Pharma
Novartis
Pharma CEOs
Vas Narasimhan
drug launches
JPMHC 2020
Flag link:
Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report
Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report
Endpoints
SMA
Roche
risdiplam
Biogen
Novartis
drug pricing
Flag link:
JPM kickoff: Gilead's deal ideal, Novartis' image-polishing, Teva's shutdown tally and one CEO's word on another
JPM kickoff: Gilead's deal ideal, Novartis' image-polishing, Teva's shutdown tally and one CEO's word on another
Fierce Pharma
JPMHC 2020
Teva Pharmaceuticals
Novartis
Gilead Sciences
M&A
Pharma CEOs
Flag link:
JPM: With new ethics plan, Novartis chief puts his money where his mouth is
JPM: With new ethics plan, Novartis chief puts his money where his mouth is
Fierce Pharma
Novartis
ethics
Pharma CEOs
Vas Narasimhan
JPMHC 2020
Flag link:
Aduro's staffers feel the sting, again, after Novartis walks away
Aduro's staffers feel the sting, again, after Novartis walks away
Fierce Biotech
Aduro BioTech
layoffs
Novartis
Flag link:
A big finish confirms 2019 as a takeover year to remember
A big finish confirms 2019 as a takeover year to remember
EP Vantage
M&A
AbbVie
Allergan
Astellas
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Flag link:
Novartis, Merck and Allergan raise drug prices to start 2020, joining Big Pharma peers
Novartis, Merck and Allergan raise drug prices to start 2020, joining Big Pharma peers
Fierce Pharma
drug pricing
Merck
Allergan
Novartis
Flag link:
3 Rare Disease Drug Launches to Watch in 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
Four Major Biopharma Scandals in 2019
Four Major Biopharma Scandals in 2019
BioSpace
scandal
Novartis
Zolgensma
data manipulation
China
CRISPR
IP theft
Purdue Pharma
Sackler family
oxycontin
Flag link:
Is there a future for pharma in neuro?
Is there a future for pharma in neuro?
Fierce Biotech
Neuroscience
R&D
Eli Lilly
Amgen
GSK
Novartis
Flag link:
Zolgensma for free? Yes, but advocates worry about Novartis' lottery-style giveaway
Zolgensma for free? Yes, but advocates worry about Novartis' lottery-style giveaway
Fierce Pharma
Novartis
Zolgensma
SMA
gene therapy
drug pricing
patients
Flag link:
Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis
Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis
Endpoints
Novartis
Akcea
Ionis
AKCEA-APO(a)-L
ACEKA-APOCIII-L
Flag link:
Aduro stung as Novartis drops work on STING drug
Aduro stung as Novartis drops work on STING drug
Fierce Biotech
Aduro BioTech
Novartis
SEC
ADU-S100
Flag link:
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Pharmaforum
Novartis
Europe
GSK
Sanofi
AstraZeneca
Roche
Flag link:
How Novartis' cancer drug Tasigna restores critical dopamine that's lost to Parkinson's disease
How Novartis' cancer drug Tasigna restores critical dopamine that's lost to Parkinson's disease
Fierce Biotech
Tasigna
Novartis
Parkinson's Disease
Flag link:

Pages